Symptom dynamics through multiphase treatment in acute myeloid leukemia: a cross-lagged panel network analysis.
1/5 보강
[OBJECTIVE] To construct symptom network for acute myeloid leukemia (AML) patients at different stages of treatment, explore the longitudinal relationships among 31 symptoms at different points, ident
APA
Liu Q, Chen Y, et al. (2025). Symptom dynamics through multiphase treatment in acute myeloid leukemia: a cross-lagged panel network analysis.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33(12), 1151. https://doi.org/10.1007/s00520-025-10220-6
MLA
Liu Q, et al.. "Symptom dynamics through multiphase treatment in acute myeloid leukemia: a cross-lagged panel network analysis.." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol. 33, no. 12, 2025, pp. 1151.
PMID
41318732 ↗
Abstract 한글 요약
[OBJECTIVE] To construct symptom network for acute myeloid leukemia (AML) patients at different stages of treatment, explore the longitudinal relationships among 31 symptoms at different points, identify key causal symptoms, and determine optimal intervention time windows.
[METHODS] AML patients admitted between July 2024 and May 2025 for chemotherapy were enrolled. Symptom incidence was assessed using the Chinese version of the Memorial Symptom Assessment Scale (MSAS-Ch) at three points: the day before chemotherapy initiation (T1), chemotherapy completion day (T2), and seven days post-chemotherapy (T3).Cross-lagged panel network (CLPN) modeling was applied to analyze longitudinal mechanisms among 31 core symptoms across three critical treatment phases.
[RESULTS] Of 275 enrolled AML patients (mean age = 56.02 ± 13.96 years), fatigue and feeling sad were the most prevalent symptoms across T1, T2, and T3. CLPN analysis identified key cross-lagged paths: difficulty swallowing (S22) → loss of appetite (S20) from T1 → T2 and weight loss (S26) → loss of appetite (S20) from T2 → T3. Predictive analysis showed feeling sad (S16) had the highest out-predictive strength in T1 → T2, while weight loss (S26) had the highest out-predictive strength in T2 → T3. Shortness of breath (S14) exhibited the highest in-predictive strength in T1 → T2, and loss of appetite (S20) had the highest in-predictive strength in T2 → T3. Centrality analysis revealed feeling sad (S16) and mental tension (S5) as the top out-strength nodes in T1 → T2, whereas mouth ulcers (S24) and weight loss (S26) were dominant in T2 → T3.
[CONCLUSIONS] AML symptom management should focus on the dynamic interplay of core symptoms, particularly during T2, providing targeted nutritional and psychological support guided by causal pathways to improve patient outcomes and quality of life. Future models integrating physiological data and treatment plans could enhance symptom prediction and management.
[METHODS] AML patients admitted between July 2024 and May 2025 for chemotherapy were enrolled. Symptom incidence was assessed using the Chinese version of the Memorial Symptom Assessment Scale (MSAS-Ch) at three points: the day before chemotherapy initiation (T1), chemotherapy completion day (T2), and seven days post-chemotherapy (T3).Cross-lagged panel network (CLPN) modeling was applied to analyze longitudinal mechanisms among 31 core symptoms across three critical treatment phases.
[RESULTS] Of 275 enrolled AML patients (mean age = 56.02 ± 13.96 years), fatigue and feeling sad were the most prevalent symptoms across T1, T2, and T3. CLPN analysis identified key cross-lagged paths: difficulty swallowing (S22) → loss of appetite (S20) from T1 → T2 and weight loss (S26) → loss of appetite (S20) from T2 → T3. Predictive analysis showed feeling sad (S16) had the highest out-predictive strength in T1 → T2, while weight loss (S26) had the highest out-predictive strength in T2 → T3. Shortness of breath (S14) exhibited the highest in-predictive strength in T1 → T2, and loss of appetite (S20) had the highest in-predictive strength in T2 → T3. Centrality analysis revealed feeling sad (S16) and mental tension (S5) as the top out-strength nodes in T1 → T2, whereas mouth ulcers (S24) and weight loss (S26) were dominant in T2 → T3.
[CONCLUSIONS] AML symptom management should focus on the dynamic interplay of core symptoms, particularly during T2, providing targeted nutritional and psychological support guided by causal pathways to improve patient outcomes and quality of life. Future models integrating physiological data and treatment plans could enhance symptom prediction and management.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- A Novel Preoperative Design to Address Dermatochalasis in Asian Upper Blepharoplasty.
- Sohlh2 inhibited the angiogenesis of hepatocellular carcinoma through the HIF-1α/VEGFA pathway.
- Integrated multi-omics, spatial profiling and organoid modeling drive transformative advances in chronic liver disease and hepatocellular carcinoma immunomicroenvironment research.
- Pharmacologic modulation of the SAT1-N1-acetylspermidine axis is associated with enhanced chemotherapy cytotoxicity in T-LBL/ALL cells.
- Integrative multi-omics and machine learning reveals the spatial niche distribution and role of CYP27A1TAMs in immunotherapy response in non-small cell lung cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.